Pure Global
NCT05402553

The Efficacy of Adjunctive Use of Ondansetron in Patients With Sepsis and Septic Shock

Noha Mansour·Phase 1/2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sepsis,Septic Shock
Drug/Device/Intervention
Ondansetron
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Noha Mansour
Funder
Mansoura University
Location
Tanta, Egypt
Timeline & enrollment
Phase
Phase 1/2
Start date
Apr 24, 2022
End date
Oct 01, 2022
Enrollment
40 participants
Primary outcome

Sequential organ failure assessment (SOFA score)

Summary

Sepsis is a systemic inflammatory response that has deleterious effects and considered the
 leading cause of death in critically ill patients 1 . One of the hallmarks of severe sepsis
 is the progressive, injurious inflammatory response to infection, mediated by the excessive
 release of inflammatory mediators and consequently, associated with multiple organs damage 2
 . Various studies have demonstrated that adverse outcomes in sepsis patients are closely
 related to the development of myocardial dysfunction 3 . The mortality of sepsis combined
 with cardiac functional insufficiency has increased significantly to 70%-90% 4 . Therefore,
 targeting cardiac insufficiency and heart injury may represent a novel treatment strategy.
 Several reports documented critical involvement of serotonin 5-hydroxytryptamine in the
 pathogenesis of sepsis. The aim of the current study is to evaluate the efficacy of
 ondansetron adjuvant use in patients with sepsis and septic shock.

ICD-10 classifications
Septic shockOther sepsisOther specified sepsisSepsis, unspecifiedSepsis due to other specified staphylococcus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05402553
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05402553 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Noha Mansour and is currently Recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.